StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
JPMorgan Downgrades ResMed (RMD) to Neutral
August 12, 2022 9:38 AM
JPMorgan analyst David Low downgraded ResMed (NYSE: RMD) from Overweight to Neutral with a price target of $250.00 (from $255.00).The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Next Articles
CLSA Downgrades ResMed (RMD:AU) (RMD) to Outperform (2), 'High near-term expectations may detract from long-term tailwinds'
August 15, 2022 6:31 AM
Form 10-K RESMED INC For: Jun 30
August 12, 2022 6:08 AM
Form 8-K/A RESMED INC For: Jun 13
August 12, 2022 6:08 AM
RBC Capital Downgrades ResMed (RMD) to Sector Perform
August 12, 2022 5:59 AM
ResMed (RMD) PT Raised to $250 at Wolfe Research
August 12, 2022 5:06 AM
ResMed (RMD) PT Raised to $222 at Morgan Stanley
August 12, 2022 3:41 AM
Citi Downgrades ResMed (RMD:AU) (RMD) to Neutral
August 12, 2022 3:37 AM
ResMed (RMD:AU) (RMD) PT Raised to AUD31.70 at Morgan Stanley
August 12, 2022 3:36 AM
Form 8-K RESMED INC For: Aug 11
August 11, 2022 4:09 PM
ResMed (RMD) Tops Q4 EPS by 4c
August 11, 2022 4:08 PM
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022
August 11, 2022 4:05 PM
